C J McDaniel1, A S Chitnis2, P M Barry2, N Shah3. 1. Office of State, Trial, Local and Territorial Support, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Tuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases California Department of Public Health, Richmond, California, USA. 2. Tuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases California Department of Public Health, Richmond, California, USA. 3. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Tuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases California Department of Public Health, Richmond, California, USA.
Abstract
BACKGROUND: Incarcerated persons are disproportionately diagnosed with tuberculosis (TB). California has the second highest inmate population in the United States, but reports the highest number of cases. OBJECTIVE: To describe the TB epidemiology among incarcerated patients in California. METHODS: Trends in incidence were assessed using Poisson regression, and trends in percentage were assessed using weighted linear regression. Demographic and clinical characteristics were compared using χ2 or Mann-Whitney U tests. RESULTS: During 1993-2013, of the 64 090 TB cases reported, 2323 (4%) were correctional facility residents. Incidence in correctional facilities decreased until 2006 (annual per cent change [APC] -12.3%, 95%CI -14.4 to -10.1), but has since stabilized (APC 4.4%, 95%CI -2.1 to 11.4). Compared with state prisoners, federal prisoners were more likely to be male (98%, P = 0.03), persons arriving in the United States within 5 years of diagnosis (62%, P < 0.001), and born in Mexico (88%, P = 0.02), whereas local jail inmates were more likely to have a history of substance use (75%, P < 0.001) and homelessness (35%, P < 0.001). CONCLUSIONS: TB incidence in correctional facilities had steadily declined over the last two decades, but has recently leveled out. To promote further reduction in incidence among diverse incarcerated populations, health departments and correctional facilities should strengthen collaboration by conducting TB risk-based assessments.
BACKGROUND: Incarcerated persons are disproportionately diagnosed with tuberculosis (TB). California has the second highest inmate population in the United States, but reports the highest number of cases. OBJECTIVE: To describe the TB epidemiology among incarcerated patients in California. METHODS: Trends in incidence were assessed using Poisson regression, and trends in percentage were assessed using weighted linear regression. Demographic and clinical characteristics were compared using χ2 or Mann-Whitney U tests. RESULTS: During 1993-2013, of the 64 090 TB cases reported, 2323 (4%) were correctional facility residents. Incidence in correctional facilities decreased until 2006 (annual per cent change [APC] -12.3%, 95%CI -14.4 to -10.1), but has since stabilized (APC 4.4%, 95%CI -2.1 to 11.4). Compared with state prisoners, federal prisoners were more likely to be male (98%, P = 0.03), persons arriving in the United States within 5 years of diagnosis (62%, P < 0.001), and born in Mexico (88%, P = 0.02), whereas local jail inmates were more likely to have a history of substance use (75%, P < 0.001) and homelessness (35%, P < 0.001). CONCLUSIONS: TB incidence in correctional facilities had steadily declined over the last two decades, but has recently leveled out. To promote further reduction in incidence among diverse incarcerated populations, health departments and correctional facilities should strengthen collaboration by conducting TB risk-based assessments.
Authors: S Bur; J E Golub; J A Armstrong; K Myers; B H Johnson; D Mazo; J F Fielder; H Rutz; G Maltas; R McClain; W A Cronin; N G Baruch; L F Barker; W Benjamin; T R Sterling Journal: Int J Tuberc Lung Dis Date: 2003-12 Impact factor: 2.373
Authors: Janet C Mohle-Boetani; Vanessa Miguelino; Daniel H Dewsnup; Edward Desmond; Evalyn Horowitz; Stephen H Waterman; Joseph Bick Journal: Clin Infect Dis Date: 2002-01-17 Impact factor: 9.079
Authors: S E Valway; S B Richards; J Kovacovich; R B Greifinger; J T Crawford; S W Dooley Journal: Am J Epidemiol Date: 1994-07-15 Impact factor: 4.897
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Linda Bauman; Karina W Davidson; John W Epling; Francisco A R García; Jessica Herzstein; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael P Pignone Journal: JAMA Date: 2016-09-06 Impact factor: 56.272
Authors: Maria Juarez-Reyes; Mark Gallivan; Alexander Chyorny; Linda O'Keeffe; Neha S Shah Journal: Open Forum Infect Dis Date: 2016-01-06 Impact factor: 3.835
Authors: Barne Willie; Avi J Hakim; Steven G Badman; Damian Weikum; Rebecca Narokobi; Kelsey Coy; Josephine Gabuzzi; Simon Pekon; Samson Gene; Angelyn Amos; Martha Kupul; Parker Hou; Nick M Dala; David M Whiley; Johanna Wapling; John M Kaldor; Andrew J Vallely; Angela Kelly-Hanku Journal: Trop Med Health Date: 2021-01-13